Evidence map›Paper›PMID 24917953›Full record

ArticleUnited European gastroenterology journal2013

Lactose malabsorption and intolerance: pathogenesis, diagnosis and treatment.

Benjamin Misselwitz, Daniel Pohl, Heiko Frühauf, Michael Fried, Stephan R Vavricka, Mark Fox

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in United European gastroenterology journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05100719 (The Role of Irritable Bowel Syndrome in Lactose Intolerance), which is not on this map. Cited by 61 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 3 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05100719 nanot yet recruitingnot on this mapstarted 2022, after this paper: background citation

The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION Trial): Protocol of a Multicentre Randomized Controlled Clinical Trial

TypeinterventionalSponsorUniversity of PecsRan2022 to 2026Enrolled200ConditionsIrritable Bowel Syndrome, Lactose Intolerance, Lactose MalabsorptionArmsalverine-citrate + simethicone and lactase, alverin-citrate + simethicone with placebo
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 222 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Benjamin MisselwitzUniversity Hospital Zürich, Zürich, Switzerland.
Daniel PohlUniversity Hospital Zürich, Zürich, Switzerland.
Heiko FrühaufTriemli-Hospital, Zürich, Zürich, Switzerland.
Michael FriedUniversity Hospital Zürich, Zürich, Switzerland.
Stephan R VavrickaTriemli-Hospital, Zürich, Zürich, Switzerland.
Mark FoxNottingham University Hospital, Nottingham, UK.
University Hospital of Zurich · CHTriemli Hospital · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lactose malabsorption is a common condition caused by reduced expression or activity of lactase in the small intestine. In such patients, lactose intolerance is characterized by abdominal symptoms (e.g. nausea, bloating, and pain) after ingestion of dairy products. The genetic basis of lactose malabsorption is established and several tests for this condition are available, including genetic, endoscopic, and H2-breath tests. In contrast, lactose intolerance is less well understood. Recent studies show that the risk of symptoms after lactose ingestion depends on the dose of lactose, lactase expression, intestinal flora, and sensitivity of the gastrointestinal tract. Lactose intolerance has recently been defined as symptoms developing after ingestion of lactose which do not develop after placebo challenge in a person with lactose maldigestion. Such blinded testing might be especially important in those with functional gastrointestinal diseases in whom self-reported lactose intolerance is common. However, placebo-controlled testing is not part of current clinical practice. Updated protocols and high-quality outcome studies are needed. Treatment options of lactose intolerance include lactose-reduced diet and enzyme replacement. Documenting the response to multiple doses can guide rational dietary management; however, the clinical utility of this strategy has not been tested. This review summarizes the genetic basis, diagnosis, and treatment of lactose malabsorption and intolerance.

Indexed as

Blinded testingFODMAPgenetic testhydrogen breath testirritable bowel syndromelactase deficiencylactose intolerancelactose malabsorptionlactose maldigestionmultiple-dose testing

Identifiers

PMID24917953
PMCPMC4040760
OpenAlexW2107665223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.